Scientific Opinion on the substantiation of health claims related to isomalto-oligosaccharides and reduction of post-prandial glycaemic responses (ID 798), and increase in the frequency of daily bowel movements (ID 800) pursuant to Article 13(1) of

Tabs

Article
EFSA Journal 2010;8(10):1801 [14 pp.].
doi
10.2903/j.efsa.2010.1801
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
Panel Members
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Acknowledgement

The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens.

Contact
Type
Opinion of the Scientific Committee/Scientific Panel
On Request From
European Commission
Question Number
EFSA-Q-2008-1585
EFSA-Q-2008-1587
Adopted
10 September 2010
Published
19 October 2010
Affiliation
European Food Safety Authority (EFSA), Parma, Italy
Note
Article (195.87 KB)195.87 KB
Summary

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to isomalto-oligosaccharides and reduction of post-prandial glycaemic responses, and increase in the frequency of daily bowel movements. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.

The food constituent that is the subject of the health claims is isomalto-oligosaccharides. The Panel considers that isomalto-oligosaccharides is sufficiently characterised.

Reduction of post-prandial glycaemic responses

The claimed effect is “low glycaemic index”. The target population is assumed to be individuals willing to reduce their post-prandial glycaemic responses. In the context of the proposed wording, the Panel assumes that the claimed effect refers to the reduction of post-prandial glycaemic responses. The Panel considers that the reduction of post-prandial glycaemic responses (as long as post-prandial insulinaemic responses are not disproportionally increased) may be a beneficial physiological effect.

No references were provided from which conclusions could be drawn for the scientific substantiation of the claimed effect.
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of isomalto-oligosaccharides and the reduction of post-prandial glycaemic responses.

Increase in the frequency of daily bowel movements

The claimed effect is “normal bowel function/gastrointestinal function/colonic function”. In the context of the clarifications provided by Member States, the Panel assumes that the claimed effect is related to an increase in the frequency of daily bowel movements. The target population is assumed to be individuals with constipation. The Panel considers that an increase in the frequency of daily bowel movements within the normal range might be a beneficial physiological effect.

No human studies were provided from which conclusions could be drawn for the scientific substantiation of the claimed effect.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of isomalto-oligosaccharides and an increase in the frequency of daily bowel movements.

Keywords
Isomalto-oligosaccharides, glycaemic responses, blood glucose, bowel function, health claims
Print on demand
Number of Pages
14